title: [Remarks of the Zurich Discussion Panel on the gene test].
authors.forename: M
authors.initials: M
authors.lastname: Birkhäuser
authors.forename: W
authors.initials: W
authors.lastname: Braendle
authors.forename: M
authors.initials: M
authors.lastname: Breckwoldt
authors.forename: P J
authors.initials: PJ
authors.lastname: Keller
authors.forename: L
authors.initials: L
authors.lastname: Kiesel
mesh_terms: D000293:Adolescent; D000328:Adult; D001943:Breast Neoplasms / Q000097:blood / Q000201:enzymology / Q000235:genetics*; D002318:Cardiovascular Diseases / Q000235:genetics; D016022:Case-Control Studies; D015331:Cohort Studies; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics; D016889:Endometrial Neoplasms / Q000235:genetics; D004967:Estrogens / Q000097:blood; D005260:Female; D005819:Genetic Markers; D020022:Genetic Predisposition to Disease; D005820:Genetic Testing; D005838:Genotype; D020249:Hormone Replacement Therapy / Q000009:adverse effects; D006801:Humans; D009154:Mutation; D009369:Neoplasms / Q000139:chemically induced / Q000235:genetics; D010024:Osteoporosis / Q000097:blood / Q000201:enzymology / Q000235:genetics*; D010641:Phenotype; D015849:Plasminogen Inactivators / Q000235:genetics; D011110:Polymorphism, Genetic; D011247:Pregnancy; D011248:Pregnancy Complications / Q000209:etiology; D011446:Prospective Studies; D011516:Prothrombin / Q000235:genetics; D016032:Randomized Controlled Trials as Topic; D011941:Receptors, Adrenergic / Q000235:genetics; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects; D019851:Thrombophilia / Q000235:genetics; D013997:Time Factors; D014407:Tumor Cells, Cultured / Q000378:metabolism; D001749:Urinary Bladder Neoplasms / Q000235:genetics; D015262:Xenobiotics / Q000009:adverse effects
chemical_list: D004967:Estrogens; D005819:Genetic Markers; D015849:Plasminogen Inactivators; D011941:Receptors, Adrenergic; D015262:Xenobiotics; D011516:Prothrombin; D003577:Cytochrome P-450 Enzyme System